References
- Lavie CJ, O'Keefe JH, Blonde L, et al. High-density lipoprotein cholesterol: recommendations for routine testing and treatment. Postgrad Med 1990; 87(7): 36–44, 47, 51
- Milani RV, Lavie CJ. Recommendations for managing patients with low HDL-cholesterol levels. J Myocard Ischemia 1992; 4: 27–46
- Lavie CJ, Milani RV. National Cholesterol Education Program's recommendations, and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programs. Am J Cardiol 1991; 68(10): 1087–8
- Lavie CJ, Milani RV. Effects of non- pharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996; 78(11): 1286–9
- Milani RV, Lavie CJ. Prevalence and effects of nonpharmacologic treatment of “isolated” low-HDL cholesterol in patients with coronary artery disease. J Cardiopulm Rehabil 1995; 15(6): 439–44
- Lavie CJ, Milani RV. High-density lipoprotein cholesterol and coronary risk in the elderly. (Editorial) Cardiol Elderly 1994; 2: 251–2
- Lavie CJ. Lipid and lipoprotein fractions and coronary artery disease. (Editorial) Mayo Clin Proc 1993; 68(6): 618–9
- Milani RV, Lavie CJ. Lipid lowering drugs: gemfibrozil. In: Messerli FH, ed. Cardiovascular drug therapy. 2d ed. Philadelphia: Saunders, 1996: 1098–101
- Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341(6): 410–8
- Frick MH, Syvänne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96(7): 2137–43
- Lavie CJ, Milani RV. Lipid lowering drugs: nicotinic acid. In: Messerli FH, ed 8, pp 1061–7
- Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with “isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992; 69(12): 1083–5